|
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
RECRUITINGPhase 2Sponsored by The University of Texas Health Science Center at San Antonio
Actively Recruiting
PhasePhase 2
SponsorThe University of Texas Health Science Center at San Antonio
Started2026-07-06
Est. completion2030-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07470606
Summary
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥ 18 years. 2. Ability to provide informed written consent in either English or Spanish. 3. All individuals of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an Intrauterine device (IUD)) with their partner from entry into the study through 24 weeks after the last dose of Raloxifene. 4. Patients undergoing radiation therapy to the brain as a part of solid tumor cancer therapy, using intensity modulated radiation therapy (IMRT) or whole brain radiation therapy (WBRT).Willingness to adhere to planned study drug regimen, including obtaining medication from an outside pharmacy via prescription. 5. Patients must have a creatinine clearance ≥ 50 mL/min (using Cockcroft-Gault Equation). 6. Patients must not have hepatic impairment greater than Child-Pugh Score "Class A". Exclusion Criteria: 1. History of prior radiotherapy to the brain. 2. Life expectancy of \< 6 months. 3. Radiation Therapy planned is ≤ 5 fractions (e.g.stereotactic radiosurgery (SRS)or Steriotactic radiotherapy (SRT), or 5-fraction whole brain). 4. Contraindications to taking memantine and/or raloxifene based on package inserts and the clinical judgement of the treating physician . 5. The subject is unable to undergo magnetic resonance imaging (MRI) scan (e.g., has an MRI incompatible pacemaker). 6. Conditions or situations which, in the opinion of the investigator, imply the patient will be unable or not suitable to complete trial requirements or at excessive risk from trial participation. 7. Known allergy to either of the medications (Memantine or Raloxifene) used in this study or their excipients. 8. Cognitive failure as assessed by Mini Mental State Exam (MMSE) score \<17
Conditions2
Brain TumorCancer
Interventions2
Locations1 site
Mays Cancer Center, UT Health San Antonio
Find trials near these locations
Related trials
- Glutamate Inhibitors in Glioblastoma — University of Zurich
- Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases — Canadian Cancer Trials Group
- Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — Mclean Hospital
- NTS-WBRT in Brain Metastases — Massachusetts General Hospital
- Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer — UNC Lineberger Comprehensive Cancer Center
- Effect of Acetylcholinesterase Inhibitors on Bone Metabolism — Duke University
- Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) — Case Comprehensive Cancer Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorThe University of Texas Health Science Center at San Antonio
Started2026-07-06
Est. completion2030-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07470606